DENTSPLY SIRONA Inc. $XRAY Shares Purchased by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC raised its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 812.3% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 176,832 shares of the medical instruments supplier’s stock after purchasing an additional 157,448 shares during the period. Kingsview Wealth Management LLC’s holdings in DENTSPLY SIRONA were worth $2,244,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Parkside Financial Bank & Trust raised its position in shares of DENTSPLY SIRONA by 620.6% in the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 1,477 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA during the first quarter worth about $26,000. True Wealth Design LLC grew its stake in DENTSPLY SIRONA by 273.0% during the 2nd quarter. True Wealth Design LLC now owns 2,376 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 1,739 shares in the last quarter. Huntington National Bank raised its holdings in DENTSPLY SIRONA by 292.9% in the 3rd quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 2,077 shares during the last quarter. Finally, Central Pacific Bank Trust Division raised its holdings in DENTSPLY SIRONA by 100.0% in the 3rd quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Insider Activity at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier sold 82,200 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $11.14, for a total transaction of $915,708.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.50% of the company’s stock.

DENTSPLY SIRONA Stock Performance

Shares of DENTSPLY SIRONA stock opened at $13.44 on Thursday. The firm has a market cap of $2.68 billion, a PE ratio of -4.48, a price-to-earnings-growth ratio of 1.56 and a beta of 0.97. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA Inc. has a 52 week low of $9.85 and a 52 week high of $17.18. The business’s fifty day simple moving average is $12.56 and its 200-day simple moving average is $12.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The company had revenue of $961.00 million during the quarter, compared to analysts’ expectations of $926.40 million. During the same quarter last year, the firm posted $0.26 earnings per share. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.

DENTSPLY SIRONA Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.8%. The ex-dividend date of this dividend was Friday, December 26th. DENTSPLY SIRONA’s payout ratio is -21.33%.

Trending Headlines about DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director purchases: Long‑time director Gregory T. Lucier bought sizable blocks of stock on March 2 and March 3 (27,555 shares at ~$14.24 and 22,445 shares at ~$14.03), raising his ownership to ~50,000 shares — a strong insider confidence signal. InsiderTrades Article
• Positive Sentiment: Barrington Research raised its price target to $17 — an upbeat analyst action that implies meaningful upside relative to current levels and can attract buyer interest. Barrington Research PT Raise
• Positive Sentiment: Zacks upgraded XRAY from “strong sell” to “hold,” removing a negative rating and potentially supporting short‑term sentiment improvement. Zacks Upgrade
• Neutral Sentiment: Mizuho raised its price target to $16 but left a “neutral” rating — modestly positive for price targets but limited catalyst without a rating upgrade. Mizuho Note
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference (Mar 10) — a scheduled event that could provide fresh guidance or color but is not itself a guaranteed catalyst. Conference Notice
• Neutral Sentiment: Fundamental watch‑items: Coverage notes flag international revenue trends and mixed analyst targets (average PT ~$14.42) — useful context for modeling but neither clearly bullish nor bearish on its own. Zacks Analysis
• Neutral Sentiment: Short‑interest reporting appears anomalous (reports showing zero/NaN), so treat any short‑squeeze narratives as unreliable until corrected data is posted.
• Negative Sentiment: Earnings & guidance caveat: The company slightly missed quarterly EPS consensus (by ~$0.01) despite a revenue beat, and FY‑2026 guidance (1.40–1.50 EPS) sits below some sell‑side estimates (~1.84), which could cap upside if analysts lower forecasts. MarketBeat Summary

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on XRAY shares. Mizuho boosted their target price on DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Monday. Zacks Research raised DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research note on Monday. Robert W. Baird raised their target price on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Barrington Research lifted their price target on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a report on Monday. Finally, JPMorgan Chase & Co. dropped their price objective on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Friday, November 7th. Three research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, DENTSPLY SIRONA currently has an average rating of “Hold” and an average target price of $14.42.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.